Skip to main content

Table 3 Instrumental variable analysis of the impact of PTR on survival for patients with stage III locally advanced PDA in 2SRI IV model

From: Comparative effectiveness of primary tumor resection in patients with stage III pancreatic adenocarcinoma

  OS (n = 4322) DSS (n = 4055)
HR 95% CI P-value HR 95% CI P-value
PTR vs. none 0.741 0.342, 1.607 0.448 0.862 0.384–1.935 0.719
Age, years 1.013 1.010–1.017 < 0.001 1.015 1.011–1.018 < 0.001
Sex, male vs. female 1.112 1.043–1.187 0.001 1.104 1.032–1.180 0.004
Race
 Black vs. White 1.080 0.974–1.197 0.146 1.085 0.974–1.209 0.137
 Other vs. White 0.978 0.872–1.097 0.700 0.990 0.878–1.116 0.871
Primary tumor site in pancreas
 Body vs. head 0.955 0.874–1.045 0.317 0.954 0.870–1.046 0.314
 Tail vs. head 1.051 0.886–1.246 0.570 0.994 0.829–1.191 0.948
Tumor size, cm 1.003 1.001–1.005 < 0.001 1.004 1.002–1.007 < 0.001
Tumor differentiation
 II vs. I 1.157 0.981–1.366 0.084 1.196 1.005–1.424 0.044
 III vs. I 1.575 1.334–1.860 < 0.001 1.628 1.368–1.938 < 0.001
 IV vs. I 1.806 1.181–2.762 0.006 1.811 1.171–2.799 0.008
Year of diagnosis, 2010–2014 vs. 2004–2009 0.987 0.981–0.994 < 0.001 0.984 0.977–0.990 < 0.001
  1. OS, overall survival; DSS, disease-specific survival; HR, hazard ratios; CI, confidence interval. Tumor differentiation: I, well-differentiated; II, moderate- differentiated; III, poor-differentiated; IV, un-differentiated